Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | AutoHCT in DLBCL in the CAR-T era

Nirav Niranjan Shah • 18 May 2020
ASCO 2020
Diffuse Large B-Cell Lymphoma Lymphoma

Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses a study which reviewed if using autologous transplantation (autoHCT) in relapsed diffuse large B-cell lymphoma (DLBCL) was appropriate in patients only acheiving a PET/CT positive partial remission prior to HCT in the CAR-T cell era. The study reviewed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nirav Niranjan Shah

2:42
Dual-targeted anti-CD19/anti-CD20 CAR T-cells in R/R MCL: insights from a Phase I/II trial
Nirav Niranjan Shah • 11 Dec 2023
1:35
Pirtobrutinib in R/R FL: results from the BRUIN study
Nirav Niranjan Shah • 11 Dec 2023
Novel therapies in NHL: BTK inhibitors & degraders
Nirav Niranjan Shah et al. • 17 Oct 2023
2:13
Phase II trial of split-dose R-CHOP for older patients with DLBCL
Nirav Niranjan Shah • 4 Jun 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals